Status:

UNKNOWN

Technical Evaluation of Earswitch Phase B

Lead Sponsor:

University of Bath

Collaborating Sponsors:

National Institute for Health Research, United Kingdom

Earswitch Ltd.

Conditions:

Motor Neuron Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The Earswitch is a demonstrated proof-of-concept that detects the voluntary contraction of a small muscle in the ear, called the tensor tympani (TT) muscle, which can be effectively used as an input s...

Detailed Description

Following recruitment and screening there are a number of different stages for the trial: 1. Initial face-to-face appointment (Clinical groups 2,3, and 4) 2. At-home setup (Clinical group 1) 3. At-ho...

Eligibility Criteria

Inclusion

  • For all participants (Clinical groups 1, 2, 3, and 4) the following inclusion criteria will apply:
  • Aged 18 and older.
  • Able to give informed consent.
  • Access to an internet-connected device (e.g., laptop/PC/ tablet/smart phone) allowing connection to the Earswitch web based trial system.
  • Ability to operate, or have someone operate on their behalf, a web browser-based interface to respond to questionnaires.
  • Normal or corrected-to-normal vision.
  • Require the use of an assistive device (defined in Appendix….) in everyday life (Clinical group 1 only).
  • For clinical groups 1, 2, and 3 the following will also apply:
  • Able to voluntarily contract the tensor tympani muscle "in isolation" by self-identification, i.e., able to rumble the ear(s) "in isolation".
  • For clinical group 4 the following will also apply:
  • Unable to voluntarily contract their tensor tympani muscle in isolation by self-identification, i.e., unable to rumble the ear(s) "in isolation".
  • For clinical group 1 the following will also apply:
  • Individual's must require, or benefit from, the use of an assistive device in everyday life. For example, for use with communication, environmental control and/or mobility (excluding simple mechanical devices for example manual wheelchairs/walkers and frames) and excluding hearing-aids and visual aids.
  • For clinical group 2 the following will also apply:
  • Individuals must have a mild to moderate motor neurodisabilities and not require electronic assistive or communication (AAC) technology. The definition of mild to moderate motor-neurological disability is broad and will include participants with mild to moderate motor disabilities not requiring assistive technology (including MND/ Multiple Sclerosis/Parkinson's /Cerebral Palsy /Stroke / Post head injury /other rare degenerative diseases).
  • Exclusion criteria
  • The following exclusion criteria will apply:
  • Those who do not have the capacity to understand the study and consent (e.g., severe learning disabilities).
  • Inability to communicate either directly to the researcher or through a carer or communication partner and therefore inability to provide consent.
  • Contraindication to use of EarSwitch including receiving treatment for an intercurrent ear infection or experiencing ear discharge or pain.
  • Unable to view eardrum despite removal of ear-wax by ear micro-suction.

Exclusion

    Key Trial Info

    Start Date :

    April 1 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 1 2025

    Estimated Enrollment :

    150 Patients enrolled

    Trial Details

    Trial ID

    NCT06090448

    Start Date

    April 1 2024

    End Date

    April 1 2025

    Last Update

    December 14 2023

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Technical Evaluation of Earswitch Phase B | DecenTrialz